Prostatype Genomics (PROGEN) Stock Overview
Prostatype Genomics AB manufactures, markets, and sells prognostic gene tests. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PROGEN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Prostatype Genomics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.73 |
| 52 Week High | SEK 9.00 |
| 52 Week Low | SEK 0.28 |
| Beta | 2.16 |
| 1 Month Change | 349.35% |
| 3 Month Change | 202.45% |
| 1 Year Change | -78.38% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| PROGEN | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -6.0% | 0.3% | 0.2% |
| 1Y | -78.4% | -4.8% | 5.2% |
Return vs Industry: PROGEN underperformed the Swedish Biotechs industry which returned -4.8% over the past year.
Return vs Market: PROGEN underperformed the Swedish Market which returned 5.2% over the past year.
Price Volatility
| PROGEN volatility | |
|---|---|
| PROGEN Average Weekly Movement | 32.9% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 11.6% |
| 10% least volatile stocks in SE Market | 3.0% |
Stable Share Price: PROGEN's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: PROGEN's weekly volatility has increased from 25% to 33% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 6 | Fredrik Rickman | www.prostatypegenomics.com |
Prostatype Genomics AB manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision.
Prostatype Genomics AB (publ) Fundamentals Summary
| PROGEN fundamental statistics | |
|---|---|
| Market cap | SEK 102.40m |
| Earnings (TTM) | -SEK 45.31m |
| Revenue (TTM) | SEK 715.00k |
Is PROGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PROGEN income statement (TTM) | |
|---|---|
| Revenue | SEK 715.00k |
| Cost of Revenue | SEK 21.80m |
| Gross Profit | -SEK 21.08m |
| Other Expenses | SEK 24.23m |
| Earnings | -SEK 45.31m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Feb 12, 2026
| Earnings per share (EPS) | -0.77 |
| Gross Margin | -2,948.25% |
| Net Profit Margin | -6,336.50% |
| Debt/Equity Ratio | 0% |
How did PROGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/03 21:59 |
| End of Day Share Price | 2026/02/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prostatype Genomics AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Johan Unnerus | Redeye |